AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
Original Article: AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study